Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis-Reference-Cited by-同舟云学术

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis

Published:2018-12-26 Issue:1 Volume:6 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Ciardi Maria R¹^ORCID,Iannetta Marco¹^ORCID,Zingaropoli Maria A¹^ORCID,Salpini Romina²^ORCID,Aragri Marianna²,Annecca Rosanna³,Pontecorvo Simona³^ORCID,Altieri Marta³,Russo Gianluca¹^ORCID,Svicher Valentina²^ORCID,Mastroianni Claudio M¹^ORCID,Vullo Vincenzo¹^ORCID

Affiliation:

1. Department of Public Health and Infectious Diseases, Sapienza, University of Rome, Rome, Italy

2. Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy

3. Department of Human Neurosciences, Sapienza, University of Rome, Rome, Italy

Abstract

Abstract Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ocrelizumab. HBV reactivation was monitored with HBV-DNA and HBV surface antigen periodic assessment. Anti-HBV treatment with entecavir was started after HBV-DNA detection. Ocrelizumab can reactivate viral replication in patients with resolved HBV infection. HBV reactivation monitoring seems an effective and safe option for the management of these patients. More studies are needed to assess the optimal management of HBV reactivation in MS patients on ocrelizumab treatment.

Funder

Sapienza Università di Roma

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

http://academic.oup.com/ofid/article-pdf/6/1/ofy356/33576913/ofy356.pdf

Reference13 articles.

1. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis;Hauser;N Engl J Med,2017

2. Ocrelizumab versus placebo in primary progressive multiple sclerosis;Montalban;N Engl J Med,2017

3. Ocrelizumab and other CD20+ B-cell-depleting therapies in multiple sclerosis;Gelfand;Neurotherapeutics,2017